research | CARLAT PUBLISHING

Clinical Update

Six Recent Disappointments in Psychiatric Research

February 1, 2024

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken has no financial relationships with companies related to this material.

Find out where standard therapies like cariprazine and esketamine have failed in recent trials, along with novel medications like minocycline, zuranolone, pimavanserin, and NAC.

12 New Findings on Quetiapine

June 6, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

12 clinically relevant findings from the past 3 years on quetiapine (Seroquel), including new side effects, dosing strategies, withdrawal phenomena, and new uses in bipolar with OCD.

How to Prescribe Omega-3 Fatty Acids

March 4, 2022

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Omega-3s are effective as augmentation of mood stabilizers in bipolar depression, and in some cases, they improve negative symptoms in early schizophrenia. The research is vast, but we narrow down when and how to use omega-3s in real-world practice.

Genetic Testing in Depression

September 10, 2021

Thomas Jordan, MD.

Thomas Jordan, MD. Dr. Jordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Randomized controlled trials have not been kind to commercial pharmacogenetic panels, but will Genecept’s fate be any different?

Two Negative Studies of Mirtazapine and Riluzole for PTSD in Veterans

June 29, 2021

Richard Moldawsky, MD.

Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Medications don’t have a good track record in PTSD, particularly in combat related trauma. Here we review two controlled trials where an old standby (mirtazapine) and a hopeful contender (riluzole) come up short.

Shining a Light on PTSD

June 29, 2021

Edmund S. Higgins, MD.

Edmund Higgins, MD Dr. Higgins has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This first-of-its-kind study looked at lightbox in PTSD with a randomized, placebo-controlled design.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.

RESEARCH UPDATE

Two Augmentation Strategies Compared in Bipolar I

September 3, 2020

Richard Moldawsky, MD

Richard J. Moldawsky, MD. Dr. Moldawsky has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Carbamazepine or valproic acid? Both have been used to augment lithium for decades, but which one works best? A new trial tests them head-to-head.

Amphetamines and Topiramate for Cocaine Use Disorder

June 10, 2020

Rehan Aziz, MD.

Rehan Aziz, MD. Dr Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Small studies have shown promise for treating cocaine use disorder with combination amphetamine salts/topiramate. In this larger trial, the combination was tested against a placebo.

Does Baclofen Titrated to High Doses Reduce Alcohol Use?

June 10, 2020

Thomas Jordan, MD.

Thomas Jordan, MD. Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Previous trials of baclofen for alcohol use disorder have used fixed or rather low doses, and the results have been mixed. This was the first randomized trial to allow up-titration of the dose depending on the patient’s response.